Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
Open Access
- 19 March 2013
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 108 (8) , 1560-1565
Abstract
The past few years have witnessed something of a renaissance in the field of cancer immunotherapy, relating largely to the clinical advances that have been associated with the development of monoclonal antibodies targeting the immune inhibitory co-receptors CTLA-4 and PD-1 and to the pursuit of genetically modified antigen-redirected adoptive T-cell therapies. These advances are based on a more substantial understanding of the factors restricting effective immune therapies that has been derived from the study of pre-clinical models of tumour growth in immune competent mice. Just as the recognition of the importance of positive co-stimulatory signaling has been instrumental to recent advances in the development of genetically modified antigen-specific adoptive cellular therapies, an increasing awareness of the ability of tumours to subvert multiple immune inhibitory pathways, effectively blunting the development or expansion of any anti-tumour immunity, is fostering the development of novel therapies that appear active as monotherapies but may achieve their greatest impact in combinatorial regimens. This mini-review will focus on attempts to target co-inhibitory members of the immunoglobulin superfamily.Keywords
This publication has 35 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Restoring function in exhausted CD8 T cells during chronic viral infectionNature, 2005
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct MechanismsMolecular and Cellular Biology, 2005
- B7-H1 Determines Accumulation and Deletion of Intrahepatic CD8+ T LymphocytesImmunity, 2004
- B7x: A widely expressed B7 family member that inhibits T cell activationProceedings of the National Academy of Sciences, 2003
- IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicityNature, 2001
- Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying ImmunoreceptorImmunity, 1999
- Lymphoproliferation in CTLA-4–Deficient Mice Is Mediated by Costimulation-Dependent Activation of CD4 + T CellsImmunity, 1997
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- IMMUNOLOGICAL ASPECTS OF MALIGNANT DISEASEThe Lancet, 1967